Characteristics of patients with newly diagnosed acute myeloid leukemia not receiving treatment
Oudai Alkabbani(Mayo Clinic in Arizona), Aref Al‐Kali(Mayo Clinic), Cecilia Arana Yi(Mayo Clinic Hospital), Mithun Vinod Shah(Mayo Clinic in Arizona), Dragan Jevremović(Mayo Clinic in Arizona), James M. Foran(Memorial Sloan Kettering Cancer Center), Aasiya Matin(Mayo Clinic in Arizona), Hassan B. Alkhateeb(Mayo Clinic), Yael Kusne(WinnMed), Mehrdad Hefazi(Mayo Clinic), Antoine N. Saliba(Mayo Clinic in Arizona), Patricia T. Greipp(Mayo Clinic), Talha Badar(Mayo Clinic in Florida), Rong He(Mayo Clinic), Kebede H. Begna(Mayo Clinic), William J. Hogan(Mayo Clinic), Kurt Bessonen(Mayo Clinic in Arizona), Mark R. Litzow(Mayo Clinic in Arizona), Yazan Jabban(Mayo Clinic), David S. Viswanatha(Mayo Clinic), Mrinal M. Patnaik(Mayo Clinic), Abhishek A. Mangaonkar(Mayo Clinic)
Cited by 0
Related Papers
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Anthracycline Dose Intensification in Acute Myeloid Leukemia
|New England Journal of Medicine|2009|907